Otsuka Pharmaceutical Factory and Fresenius Kabi Japan enter into an exclusive distribution agreement of HES products, including the newly approved Voluven 6% (127KB)
Notice of the Result of Share Repurchase through ToSTNeT-3 (104KB)
Notice of Acquisition of Own Shares through ToSTNeT-3 (102KB)
Otsuka Holdings Announces Personnel Changes (113KB)
Otsuka Holdings Co., Ltd. to Acquire Own Shares (122KB)
Otsuka Holdings announces FY2012 financial results.
Otsuka announces 2013 first quarter U.S. net sales figures of ABILIFY® (129KB)
Lundbeck and Otsuka Further Expand Alliance and Enter Into Collaboration For the Development and Commercialization of Lu AE58054 In Development For Alzheimer’s Disease (243KB)
Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin (117KB)
Otsuka Holdings held R&D Meeting.
FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia (257KB)
Otsuka announces 2012 fourth quarter U.S. net sales figures of ABILIFY® (129KB)
(127KB)
